• CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer. 

• Boehringer Ingelheim strengthens footprint in Swiss biotech innovation hub. 

Today NBE Therapeutics (NBE) a wholly owned subsidiary of  Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel. This milestone reinforces its commitment to innovation in oncology and strengthens its footprint in Switzerland’s biotech ecosystem. NBE Therapeutics, a Swiss biotech founded in 2012 that became part of Boehringer Ingelheim in 2020, plays a pivotal role in the company’s oncology research strategy. The new facility will serve as a leading research center for advancing antibody-drug conjugates (ADC) research and development, supporting Boehringer Ingelheim’s commitment to developing transformative cancer therapies to improve patients’ lives globally.  

Advancing ADC research with investment in Swiss NBE Therapeutics site 

This investment in NBE’s Basel site is a significant step toward Boehringer Ingelheim’s goal of transforming cancer care. It bolsters our robust oncology pipeline and adds on top of a recent license agreement with Synaffix B.V., Amsterdam, expanding NBE‘s ADC portfolio and the recent opening of a new facility at our oncology research site in Vienna, Austria. The new research facility will contribute to building a broad pipeline of ADCs, addressing novel tumor target space to develop next…